IP Library › Granted Patent US 12,298,037
Granted Patent B2
US 12,298,037 · App. 18/407,208 · Granted May 13, 2025

System for delivery of inactivated pathogens for contactless passive immunization

Inventor: Madhavan Pisharodi (Brownsville, TX)
Assignee: PERUMALA HOLDINGS, LLC
F24F8/22F24F13/06
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,298,037
App. No.
18/407,208
Granted
May 13, 2025
Kind
B2
Abstract

A system for delivering inactivated pathogens to an enclosure includes an air delivery system, the air delivery system comprising: (a) an air intake; (b) an air conditioning unit; (c) an air mover; (d) a UVC disinfection unit; (e) an enclosure; (f) an enclosure air entry vent; (g) an enclosure air discharge vent; and (h) an air circulation pathway going from the air intake through an air duct connected at one end to the air intake and at a second end to the enclosure air entry vent that opens into the enclosure, wherein the air duct provides a passageway through the air delivery system. A pathogen loading inlet is connected to the air circulation pathway. The enclosure is a room, a nursing home, an airplane, a train, a ship, or a critical care unit in a hospital. The enclosure can also be a free-standing and/or mobile unit.

Claims (25)

1. A system for delivering inactivated pathogens to an enclosure, comprising:

an air delivery system, the air delivery system comprising:

(a) an air intake;

(b) an air conditioning unit;

(c) an air mover;

(d) a UVC disinfection unit;

(e) an enclosure;

(f) an enclosure air entry vent;

(g) an enclosure air discharge vent;

(h) an air circulation pathway going from the air intake through an air duct connected at one end to the air intake and at a second end to the enclosure air entry vent that opens into the enclosure, wherein the air duct provides a passageway through the air delivery system; and

(i) a pathogen loading inlet connected to the air circulation pathway, wherein a predetermined quantity of pathogen is injected into the system.

2. The system as claimed in claim 1 , wherein the air mover controls a velocity of air movement through the air duct.

3. The system as claimed in claim 1 , wherein the UVC disinfection unit comprises a housing that encloses a disinfection chamber that has:

(a) a chamber wall;

(b) a chamber inlet;

(c) a chamber outlet;

(d) a centralized inner bore having an interior chamber surface facing the inner bore;

(e) a UVC light source positioned adjacent the interior chamber surface; and

(f) a helical air flow diverter centralized within the inner bore proximal the UVC light source, wherein the helical airflow diverter creates a helical path for the air circulation pathway to proceed through the disinfection chamber from the chamber inlet to the chamber outlet.

4. The system as claimed in claim 3 , wherein the air disinfection unit contains more than one UVC disinfection chamber.

5. The system as claimed in claim 1 , wherein the enclosure is a room, a nursing home, an airplane, a train, a ship, or a critical care unit in a hospital.

6. The system as claimed in claim 1 , further comprising a test chamber connected to the air circulation pathway adjacent the UVC disinfection unit.

7. The system as claimed in claim 3 , wherein the air disinfection unit contains more than one disinfection chamber.

8. The system as claimed in claim 1 , wherein the system is configured as a contactless system for immunizing humans, birds or animals.

9. The system as claimed in claim 8 , wherein the enclosure is a free-standing, mobile enclosure.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 10, 2024
From: PISHARODI, MADHAVAN, DR
To: PERUMALA HOLDINGS, LLC
Reel/Frame 066082/0647 →
Continuity (7)
Continuation In Part 18328463 · Jun 2, 2023
Continuation In Part 18058185 · Nov 22, 2022
Continuation In Part 18058185 · Nov 22, 2022
Continuation In Part 17545822 · Dec 8, 2021
Provisional Application 63479143 · Jan 9, 2023
Provisional Application 63233697 · Aug 16, 2021
Related Publication 20240142124A1 · May 2, 2024
References Cited (47)
US 3721072A · Miller · 1973 [cited by applicant]
US 3773044A · Wallace · 1973 [cited by applicant]
US 3850170A · Cox · 1974 [cited by applicant]
US 4580556A · Kondur · 1986 [cited by applicant]
US 4742760A · Horstman · 1988 [cited by applicant]
US 5656242A · Morrow et al. · 1997 [cited by applicant]
US 7185510B2 · Lee et al. · 2007 [cited by applicant]
US 8336821B2 · Shell et al. · 2012 [cited by applicant]
US 8674322B2 · Kohler · 2014 [cited by applicant]
US 11052169B1 · Pisharodi · 2021 [cited by applicant]
US 20060057020A1 · Tufo · 2006 [cited by applicant]
US 20060263276A1 · Pattee · 2006 [cited by applicant]
US 20080112845A1 · Dunn · 2008 [cited by applicant]
US 20080173178A1 · Metteer · 2008 [cited by applicant]
US 20100150793A1 · Chan · 2010 [cited by applicant]
US 20110286167A1 · Winkler · 2011 [cited by applicant]
US 20120128539A1 · Gross · 2012 [cited by examiner]
US 20120301363A1 · Kim et al. · 2012 [cited by applicant]
US 20160001108A1 · Zhou et al. · 2016 [cited by applicant]
US 20170341762A1 · Breigenzer · 2017 [cited by applicant]
US 20180250430A1 · Machovina et al. · 2018 [cited by applicant]
US 20190009912A1 · Matsui · 2019 [cited by applicant]
US 20200155667A1 · James · 2020 [cited by examiner]
WO WO2022090586A1 · 2022 [cited by examiner]
Translation of WO-2022090586-A1 (Year: 2022). [cited by examiner]
‘How a packaged system works’ (Goodman) Jul. 29, 2016, [online] retrieved from <URL: https://web.archive.org/web/20160729193422/https://www.goodmanmfg.com/resources/heating- cooling-101/how-a-packaged-system-works>. [cited by applicant]
Hankaniemi etal., Vaccine, vol. 37, Issue 40, pp. 5962-5971, (Year: 2019). [cited by applicant]
‘UVC disinfects SARS CoV 2 by induction of viral genome damage without apparent effects on viral morphology and proteins’ (Lo) Jul. 5, 2021, [online] retrieved from <URL: https://doi.org/10.1038/s41598-021-93231-7>. [cited by applicant]
‘UV Inactivation of Rotavirus and Tulane Virus Targets Different Components of the Virions’ (Araud) Feb. 3, 2020, [online] retrieved from <URL: https://doi.org/10.1128/AEM.02436-19.>. [cited by applicant]
W. C. Russell; “Adenoviruses: update on structure and function;” Journal of General Virology (2009), 90, 1-20; DOI 10.1099/vir.0.003087-0. [cited by applicant]
‘Ultraviolet A light effectively reduces bacteria and viruses including coronavirus’ (Rezale) Jul. 16, 2020, [online] retrieved from <URL: https://doi.org/10.1371/journal.pone.0236199>. [cited by applicant]
Koma T, Doi N, Suzuki A, Nagamatsu K, Yasui T, Yasutomo K, Adachi A, Minamikawa T and Nomaguchi M (2022) Major target for UV-induced complete loss of HIV-1 infectivity: A model study of single stranded RNA enveloped vir… [cited by applicant]
‘UV C irradiation is highly efective in inactivating SARS CoV 2 replication’ (Biasin) Mar. 18, 2021, [online] retrieved from <URL: https://doi.org/10.1038/s41598-021-85425-w>. [cited by applicant]
Eischeid, Anne C. et al; “Molecular Indications of Protein Damage in Adenoviruses after UV Disinfection;” Applied and Environmental Microbiology, Feb. 2011, p. 1145-1147 vol. 77, No. 3. [cited by applicant]
Araud E, Fuzawa M, Shisler JL, Li J, Nguyen TH. 2020. UV inactivation of rotavirus and Tulane virus targets different components of the virions. Appl Environ Microbiol 86:e02436-19. https://doi.org/10.1128/AEM 02436-19. [cited by applicant]
Ma B, Gundy PM, Gerba CP, Sobsey MD, Linden KG. 2021. UV inactivation of SARSCoV-2 across the UVC spectrum: KrCI* excimer, mercury-vapor, and light-emitting-diode (LED) sources. Appl Environ Microbiol 87: e01532-21. htt… [cited by applicant]
Christin Scheller; “Physicochemical properties of SARS-CoV-2 for drug targeting, virus inactivation and attenuation, vaccine formulation and quality control” Electrophoresis 2020, 41, pp. 1137-1151; Wiley-VCH Verlag Gmb… [cited by applicant]
George Devitt et al; “Mechanisms of SARS-CoV-2 Inactivation using UVC Laser Radiation” bioRxiv preprint Feb. 3, 2023.; https://doi.org/10.1101/2023.02.03.526944doi. [cited by applicant]
Ernest R. Blatchley, III et al; “SARS-CoV-2 Ultraviolet Radiation Dose-Response Behavior” SARS-CoV-2 Ultraviolet Radiation Dose-Response Behavior; Journal of Research of the National Institute of Standards and Technolog… [cited by applicant]
Ernest R. Blatchley, III et al; “Far UV-C Radiation: Current State-of Knowledge” International Ultraviolet Association; Whitepaper of The IUVA Task Force (TF) on Far UV-C Radiation for Disinfection of Air and Surfaces; … [cited by applicant]
Beck, Sara E. et al. “Wave-length dependent Damage to Adenoviral Proteins Across the Germacidal UV Spectrum” Environ. Sci. Technol. 2018, 52, 223-229. [cited by applicant]
Joshua Hadi et al; “Control Measures for SARS-CoV-2: A Review on Light-Based Inactivation of Single-Stranded RNA Viruses” Pathogens 2020, 9, 737; doi:10.3390/pathogens9090737; http://www.mdpi.com/journal/pathogens. [cited by applicant]
Sanjeev K. Bhardwaj et al “UVC-based photoinactivation as an efficient tool to control the transmission of coronaviruses” Science of the Total Environment 792 (2021) 148548; www.elsevier.com/locate/scitotenv. [cited by applicant]
Loveday, E.K.; Hain, K.S.; Kochetkova, .; Hedges, J.F.; Robison, A.; Snyder, D.T.; Brumfield, S.K.; Young, M.J.; Jutila, M.A.; Chang, C.B.; et al. Effect of Inactivation Methods on SARS-CoV-2 Virion Protein and Structur… [cited by applicant]
Naomi Takasuka et al; “A subcutaneously injected UV-inactivated SARS coronavirus vaccine elicits systemic humoral immunity in mice” International Immunology, vol. 16, No. 10, pp. 1423-1430; 2004; The Japanese Society fo… [cited by applicant]
Ong, Q. et al; “Irradiation of UVC LED 277 nm inactives coronaviruses in association to photodegradation of spike protein;” Helion 8 (2022) e11132; www.cell.com/heliyon. [cited by applicant]
Renata Sesti-Costa et al; “UV 254 nm is more efficient than UV 222 nm in inactivating SARS-CoV-2 present in human saliva;” Photodiagnosis and Photodynamic Therapy 39 (2022) 103015; https://doi.org/10.1016/j.pdpdt.2022.1… [cited by applicant]
Cited By (1)
US 12,564,627